17,261 trials
Prostatic Neoplasms · Genital Neoplasms, Male · Urogenital Neoplasms
Primary: Primary Endpoint (HIFU): Identification of New Cancers — 85; 49 biopsy-proven cancerous zones
Skin Squamous Cell Carcinoma · Appendix Adenocarcinoma · Rare Lesion
Primary: Overall Response Rate (ORR) — 2 Participants
Hematologic Malignancies
Primary: Disease-free Survival (DFS) — 57; 29; 38; 57 percentage of participants
Smoking, Tobacco · Mental Illness
Primary: Study 3: Smoking Abstinence — 3 Participants
Lipoprotein Disorder
Primary: Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 — -39.0; -74.4; -93.7; 3.1 percent change — p=<0.001
Congenital Hyperinsulinism
Primary: Median of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM at Baseline (BL) and End of Treatment (EOT) — 81.7; 72.9; 83.4…
Breast Cancer
Primary: Bone Scan Response Rate — 38.5 percentage of participants
Cirrhosis · Hepatic Encephalopathy
Primary: Serious Adverse Events Related to FMT — 0; 0; 0; 0 Participants
Glioblastoma Multiforme of Brain
Primary: Safety and Tolerability — 19; 2; 2; 2 participants
Clostridioides Difficile Infection
Primary: Rate of Clinical Cure at the Test of Cure [TOC] Visit in the Intent-to-treat [ITT] Population — 13; 15; 13; 0 Participants
Squamous Cell Carcinoma of Head and Neck
Primary: Overall Survival (OS) — 8.4; 11.3 Months — p=0.9963
Recurrent Clostridium Difficile Infection · Clostridium Difficile Infection · CDI
Primary: Recurrent Clostridium Difficile Infection (CDI) — 17; 24 Participants — p=0.22
Raynaud Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -14.32; -15.09 Number of RP attacks per week — p=0.8498
Aqueous Tear Deficiency · Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Primary: Tear Break up Time — 0.0; 2.9 seconds
Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With Adverse Events Occurring Over the Trial Period — 37; 5; 6; 12 Participants